Items where authors include "Morden, J.P."

Article

Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology. ISSN 1470-2045

Latimer, N.R. orcid.org/0000-0001-5304-5585, Abrams, K.R., Lambert, P.C. et al. (2 more authors) (2018) Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. Statistical Methods in Medical Research, 27 (3). pp. 765-784. ISSN 0962-2802

Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045

Latimer, N., Abrams, K.R., Lambert, P.C. et al. (5 more authors) (2013) Adjusting survival time estimates to account for treatment switching in randomised controlled trials – a simulation study. HEDS Discussion Paper 13/06. (Unpublished)

Monograph

Latimer, N.R., Abrams, K.R., Lambert, P.C. et al. (2 more authors) (2014) Assessing methods for dealing with treatment crossover in clinical trials: A follow-up simulation study. Discussion Paper. HEDS Discussion Paper Series (14.01). Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield , Sheffield.